*Hemophilia FIX Market Assessment. Third-Party Market Research.
†Zero median annualized spontaneous bleeding rate when dosed at 7 or 14 days in clinical trials.
‡Once well controlled (1 month without spontaneous bleeding or requiring dose adjustments on a weekly dose of ≤40 IU/kg), people 12 years and older can be transitioned to 14-day dosing.
§The average dose for people receiving prophylaxis every 7 days was 37 IU/kg and every 14 days was 73 IU/kg.
Connect Live with a Patient Advocate, a Healthcare Professional, and fellow patients from the Hemophilia B community. Learn more about about living with and managing Hemophilia B.
“On IDELVION, I can enjoy what I’m doing. I don’t have to worry as much about the impact of hemophilia B.”